Mark E. Schneiderhan

Assessment of a Point‐of‐Care Metabolic Risk Screening Program in Outpatients Receiving Antipsychotic Agents

Mark E. Schneiderhan, Catherine Batscha, Cherise Rosen · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · 2009 · 37 citations

Attenuation of Antipsychotic-Induced Hyperprolactinemia with Clozapine

Mark Bunker, Patricia A. Marken, Mark E. Schneiderhan et al. · Journal of Child and Adolescent Psychopharmacology · 1997 · 23 citations

Antipsychotic-induced Hyperprolactinemia, Conventional Antipsychotic Therapy, Psychiatry +12

Using pharmacogenomics and therapeutic drug monitoring to guide drug selection and dosing in outpatient mental health comprehensive medication management

Jacob T. Brown, Jeffrey R. Bishop, Mark E. Schneiderhan · Mental Health Clinician · 2020 · 23 citations · Full text

Drug Selection, Psychotropic Medication, Pharmacotherapy +16

Is Acetazolamide Similar to Topiramate for Reversal of Antipsychotic-Induced Weight Gain?

Mark E. Schneiderhan, Robert G. Marvin · American Journal of Therapeutics · 2007 · 17 citations

Metabolic Disorder, Psychotropic Medication, Significant Weight Loss +20

Twelve-Month Prospective Randomized Study of Pharmacists Utilizing Point-Of-Care Testing for Metabolic Syndrome and Related Conditions in Subjects Prescribed Antipsychotics

Mark E. Schneiderhan, Sara M Shuster, Cynthia Davey · The Primary Care Companion For CNS Disorders · 2014 · 15 citations · Full text